Salud financiera de hoja de balance de Avalo Therapeutics

Salud financiera controles de criterios 5/6

Avalo Therapeutics tiene un patrimonio de los accionistas total de $7.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $21.0M y $13.7M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$7.42m
Patrimonio	US$7.30m
Total pasivo	US$13.69m
Activos totales	US$20.99m

Actualizaciones recientes sobre salud financiera

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Aug 10

Recent updates

Cerecor enters into $35M debt financing agreement with Horizon Technology Finance

Jun 07

What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Mar 10

Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Jan 18

Armistice Capital adds 2.5M Cerecor shares for $6.5M

Jan 13

Cerecor slumps 12% on stock and pre-funded warrants offering

Jan 07

Cerecor gains on CERC-002 data in mid-stage COVID-19 study

Jan 05

Cerecor trades higher as FDA accepts IND application for CERC-007

Dec 22

Dosing underway in Cerecor's early-stage CERC-007 study in multiple myeloma

Dec 16

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($8.4M) de AVTX superan a sus pasivos a corto plazo ($4.6M).

Pasivo a largo plazo: Los activos a corto plazo ($8.4M) de AVTX no cubren sus pasivos a largo plazo ($9.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: AVTX está libre de deudas.

Reducción de la deuda: AVTX no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: AVTX tiene suficiente cash runway para 3 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que AVTX disponga de suficiente cash runway para 3 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Avalo Therapeutics

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Hearings Panel Grants Avalo Therapeutics an Exception from Compliance with the MVLS Rule and the Bid Price Rule and Extension of Continued Listing Until December 29, 2023

Nasdaq Determines to Delist Securities of Avalo Therapeutics

Avalo Therapeutics, Inc. Receives Notice from Nasdaq Regarding Bid Price Rule

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Recent updates

Avalo Therapeutics, Inc. Announces Board Appointments

Hearings Panel Grants Avalo Therapeutics an Exception from Compliance with the MVLS Rule and the Bid Price Rule and Extension of Continued Listing Until December 29, 2023

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Nasdaq Determines to Delist Securities of Avalo Therapeutics

AUG Therapeutics, LLC entered into a purchase agreement to acquire rights, title and interest in, assets relating to AVTX-800 Series from Avalo Therapeutics, Inc. (NasdaqCM:AVTX).

Avalo Therapeutics, Inc. Receives Notice from Nasdaq Regarding Bid Price Rule

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Insider selling

New major risk - Market cap size

Price target decreased by 93% to US$0.75

Avalo Announces Topline Data from Phase 2 Peak Trial for Avtx-002 (Quisovalimab) in Patients with Non-Eosinophilic Asthma

Insider recently bought US$56k worth of stock

Insider recently bought US$89k worth of stock

Consensus revenue estimates decrease by 79%, EPS upgraded

Consensus revenue estimates decrease by 79%, EPS upgraded

Insider recently bought US$69k worth of stock

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insider recently bought US$143k worth of stock

Full year 2022 earnings: Revenues miss analyst expectations

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. Completes Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Consensus revenue estimates increase by 43%

Consensus forecasts updated

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avalo Therapeutics, Inc. Advances B and T Lymphocyte Attenuator Agonist Fusion Protein (AVTX-008) to IND-Enabling Stage

High number of new and inexperienced directors

Avalo Therapeutics Announces Board Changes

Consensus revenue estimates increase by 190%

Price target decreased to US$11.38

Price target increased to US$53.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Price target decreased to US$30.00

Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007

Consensus revenue estimates fall by 10%

Price target decreased to US$43.50

Avalo Therapeutics announces one-for-twelve reverse stock split

Consensus forecasts updated

Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$3.95

Avalo Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$3.95

Full year 2021 earnings: Revenues miss analyst expectations

Avalo Therapeutics, Inc. Announces Executive and Board Changes

Avalo Therapeutics, Inc. Announces Chief Executive Officer Changes

Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer

Price target decreased to US$5.75

Avalo Therapeutics, Inc. Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2020)

Price target decreased to US$6.00

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

Avalo Therapeutics, Inc.(NasdaqCM:AVTX) dropped from NASDAQ Composite Index

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.19 loss in 2Q 2020)

High number of new directors

Price target decreased to US$6.80

Cerecor Inc. announced that it expects to receive $35 million in funding from Horizon Technology Finance Management, LLC

Cerecor enters into $35M debt financing agreement with Horizon Technology Finance

Consensus revenue estimates increase to US$5.18m

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.36 loss in 1Q 2020)

U.S. Food and Drug Administration Grants Fast Track Designation to CERC-002 of Cerecor Inc. for Treatment of Hospitalized Patients with COVID-19

Cerecor Inc. Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

Price target decreased to US$8.50

What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?